Anti human idh1 r132h mouse monoclonal clone h09l

With a representative section, we performed IHC with a VentanaBenchMark XT autostainer (Ventana Medical System, Inc. Tucson, AZ) according to the protocol. The antibody used was anti-human IDH1 R132H mouse monoclonal (Clone H09L, 1:80 dilution, Dianova, Hamburg, Germany). A neuropathologist (S.H. Kim) reviewed the immunohistochemical and histologic findings without information of IDH1 mutation status assessed by other methods. When the cytoplasmic expression of the IDH1 R132H was identified in glioma cells, we regarded those cases as “mutant” or “positive”.

Genomic DNA was isolated from paraffin-embedded samples of 229 patients. The DNA methylation status of the CpG islands at the MGMT promoter was determined by methylation-specific polymerase chain reaction, as described, with some modifications.^{[16 (link),17 (link)]}Representative tissue sections were assessed by immunohistochemistry, using a Ventana BenchMark XT autostainer (Ventana Medical System, Inc. Tucson, AZ) according to the manufacturer's protocols. Primary antibodies included anti-human IDH1 R132H mouse monoclonal (clone H09L, Dianova, 1:80 dilution) and anti-Ki-67 (clone Mib-1, Dako, 1:150 dilution). Samples showing cytoplasmic expression of IDH1 R132H in glioma cells were classified as positive for mutation, with all others classified as “wild-type.” MIB-1 (Ki67) score was defined as the percentage of positive nuclei among 1000 tumor cells, or as many as possible in the case of small specimens.